Marker Therapeutics expands cell therapy manufacturing
Marker Therapeutics plans to establish a new current good manufacturing practice manufacturing facility in Houston to support clinical development of multiantigen targeted-specific T-cell therapies. Read More
ImmunoPrecise identifies SARS-CoV-2 neutralizing antibodies
ImmunoPrecise Antibodies has identified several lead candidate antibodies with high neutralizing activity in vitro that are being manufactured for further testing and possible inclusion in the company's PolyTope monoclonal antibody therapy against COVID-19. Read More
Biocare Medical, Bethyl Laboratories partner for antibody development
Biocare Medical has formed a strategic partnership with Bethyl Laboratories to develop targeted antibodies for cancer research. Read More
RevImmune initiates phase II study for COVID-19 immunotherapy
RevImmune has launched a phase II clinical trial of CYT107 immune therapy for treatment of COVID-19 and is preparing to expand to the U.S. Read More
Study suggests biological age can be reduced
A pilot study conducted by TruMe Labs for Ponce de Leon Health suggests that biological age can be reduced, the company reported. Read More
Oblique, Targovax partner on anticancer treatment
Oblique Therapeutics and Targovax are partnering on anticancer treatment by combining their Oncos and Abiprot offerings. Read More
Eurofins DiscoverX expands program with Catalent
Eurofins DiscoverX has expanded its contract research organization certification program for bioassays with Catalent Biologics as the North American provider. Read More
Consortium studies body-on-a-chip technology
The Wake Forest Institute for Regenerative Medicine and Oracle Health Sciences have joined forces to develop a consortium of industry, government, and academic members to study novel approaches to establish drug safety. Read More
Celltex moves COVID-19 prophylactic to clinical trials
Celltex has received approval from the U.S. Food and Drug Administration to investigate the prophylactic efficacy of autologous adipose tissue-derived mesenchymal stem cells against COVID-19. Read More
Entos to begin phase I/II study of COVID-19 vaccine candidate
Entos Pharmaceuticals has selected two lead candidates for a pancoronavirus Fusogenix DNA vaccine (Covigenix) from its prototyping program to initiate phase I/II human clinical trials in late July. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
